You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):注射用甲苯磺酸瑞馬唑侖獲得藥品補充申請批准通知書
格隆匯 09-27 16:37

格隆匯9月27日丨恆瑞醫藥(600276.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發關於注射用甲苯磺酸瑞馬唑侖的《藥品補充申請批准通知書》。

甲苯磺酸瑞馬唑侖屬於苯二氮卓類藥物,是一種短效GABAa受體激動劑。甲苯磺酸瑞馬唑侖通過與GABAa受體結合,抑制神經元活動,從而產生鎮靜作用。甲苯磺酸瑞馬唑侖的優勢在於起效快、甦醒時間短、對呼吸及心血管系統影響小,在該品用於胃鏡診療鎮靜的Ⅲ期研究中,甲苯磺酸瑞馬唑侖組受試者的中位鎮靜誘導時間為90秒,中位鎮靜甦醒時間為6分鐘;用於結腸鏡診療鎮靜的Ⅲ期研究中,甲苯磺酸瑞馬唑侖組受試者的中位鎮靜誘導時間為90秒,中位鎮靜甦醒時間為8分鐘;上述臨牀試驗中,甲苯磺酸瑞馬唑侖組受試者低血壓發生率為5.41%(24/444),心動過緩發生率為1.13%(5/444),呼吸抑制發生率為1.58%(7/444)。因此品是相對安全、可控的麻醉/鎮靜藥物。

截至目前,注射用甲苯磺酸瑞馬唑侖相關項目累計已投入研發費用約為1.08億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account